Evidence map›Paper›PMID 15230289›Full record

ReviewLupus2004

Rationale for interleukin-6 blockade in systemic lupus erythematosus.

E Tackey, P E Lipsky, G G Illei

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lupus, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 3 syntheses or guidelines pooled it, 302 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

E TackeyOffice of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA.
P E Lipsky
G G Illei
National Institute of Arthritis and Musculoskeletal and Skin Diseases · US

Funding

B CELL REPERTOIRE ANALYSISZ01AR041127 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI PLOTZ, PAUL · 2000 to 2008
$2.1M
STUDIES OF THE PATHOGENESIS, NATURAL HISTORY &TREATMENT OF LUPUS NEPHRITISZ01AR041121 · NIAMS · ARTHRITIS, MUSCULOSKELETAL, SKIN DIS · PI LIPSKY, PETER E · 1998 to 2006
–
Intramural NIH HHS Z99 DE999999
6 · The paper itself

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities that plays an important role in immune regulation and inflammation. Among other actions, it induces terminal differentiation of B lymphocytes into antibody-forming cells and the differentiation of T cells into effector cells. IL-6 also has multiple potent proinflammatory effects. An association between IL-6 and lupus was demonstrated in murine models of SLE and blocking IL-6 improved lupus in all models tested. Data from several studies suggest that IL-6 plays a critical role in the B cell hyperactivity and immunopathology of human SLE, and may have a direct role in mediating tissue damage. Based on these data, we propose that blocking the effect of IL-6 in humans may improve lupus by interacting with the autoinflammatory process both systemically and locally.

Indexed as

Interleukin-6 InhibitorsAnimalsDisease Models, AnimalHumansInterleukin-6Lupus Erythematosus, SystemicReceptors, Interleukin-6Interleukin-6Interleukin-6 InhibitorsReceptors, Interleukin-6

Identifiers

PMID15230289
PMCPMC2014821
OpenAlexW2026527144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.